Soligenix Inc. (formerly DOR BioPharma Inc.) halted its confirmatory Phase III trial of orBec (oral beclomethasone dipropionate, or OBD) for acute gastrointestinal graft-vs.-host disease (GvHD) following stem cell transplant after an interim analysis by an independent data safety monitoring board concluded the study was "highly unlikely" to meet its predetermined efficacy endpoint. No safety concerns were raised.